Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: human insulin

First Posted Date: 2011-10-07

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 28

Registration Number: NCT01448070

Locations: 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom

Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin degludec

First Posted Date: 2011-09-21

Last Posted Date: 2019-05-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01437592

Locations: 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China

Changing Diabetes® World Tour

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes
Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2011-09-20

Last Posted Date: 2017-01-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 8304

Registration Number: NCT01437072

Locations: 🇦🇪
Novo Nordisk Investigational Site, Dubai, United Arab Emirates

A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Children With Type 1 Diabetes

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Other: No treatment given

First Posted Date: 2011-09-16

Last Posted Date: 2017-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 349

Registration Number: NCT01435642

Locations: 🇩🇿
Novo Nordisk Investigational Site, Blida, Algeria

A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin

Completed

Conditions: Genetic Disorder
Achondroplasia

Interventions: Drug: somatropin

First Posted Date: 2011-09-16

Last Posted Date: 2017-05-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 81

Registration Number: NCT01435629

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart 30

First Posted Date: 2011-09-02

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 348

Registration Number: NCT01427920

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom

Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: I.v. NNC 0113-0987
Drug: oral NNC 0113-0987
Drug: oral placebo

First Posted Date: 2011-07-29

Last Posted Date: 2013-11-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 101

Registration Number: NCT01405261

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide

First Posted Date: 2011-07-27

Last Posted Date: 2018-02-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 4121

Registration Number: NCT01403025

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Growth Disorder
Healthy
Prader-Willi Syndrome
Idiopathic Short Stature
Genetic Disorder

Interventions: Drug: somatropin

First Posted Date: 2011-07-25

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT01401244

Locations: 🇺🇸
Novo Nordisk Investigational Site, Evansville, Indiana, United States

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773

Phase 3

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia B

Interventions: Drug: nonacog beta pegol

First Posted Date: 2011-07-18

Last Posted Date: 2018-05-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 71

Registration Number: NCT01395810

Locations: 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy